These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

988 related articles for article (PubMed ID: 28216624)

  • 1. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor.
    Zhang RX; Cai P; Zhang T; Chen K; Li J; Cheng J; Pang KS; Adissu HA; Rauth AM; Wu XY
    Nanomedicine; 2016 Jul; 12(5):1279-90. PubMed ID: 26772427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
    Zhang T; Lip H; He C; Cai P; Wang Z; Henderson JT; Rauth AM; Wu XY
    Adv Healthc Mater; 2019 Sep; 8(18):e1900543. PubMed ID: 31348614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
    Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
    Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.
    Zhang RX; Zhang T; Chen K; Cheng J; Lai P; Rauth AM; Pang KS; Wu XY
    J Vis Exp; 2017 Oct; (128):. PubMed ID: 29053672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
    Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
    Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.
    Cheng B; Gao F; Maissy E; Xu P
    Acta Biomater; 2019 Jan; 84():378-390. PubMed ID: 30528604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
    Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
    Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
    Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
    Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles.
    Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR
    Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
    Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
    Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
    Godugu C; Doddapaneni R; Singh M
    Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer.
    He C; Cai P; Li J; Zhang T; Lin L; Abbasi AZ; Henderson JT; Rauth AM; Wu XY
    J Control Release; 2017 Jan; 246():98-109. PubMed ID: 28017889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
    Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
    J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low molecular weight heparin-based reduction-sensitive nanoparticles for antitumor and anti-metastasis of orthotopic breast cancer.
    Sun H; Cao D; Liu Y; Wang H; Ke X; Ci T
    Biomater Sci; 2018 Jul; 6(8):2172-2188. PubMed ID: 29942949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
    Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
    Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of photodynamic treatment and doxorubicin on triple negative breast cancer cells.
    Yousefi Sadeghloo A; Khorsandi K; Kianmehr Z
    Photochem Photobiol Sci; 2020 Nov; 19(11):1580-1589. PubMed ID: 33030191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.